2022 World Conference on Lung Cancer (ePosters)-EP16.02-014. A Comparative Analysis of Gene Alteration Detected With NGS in Tumor Tissue and Peripheral Blood in Lung Cancer

EP16.02-014. A Comparative Analysis of Gene Alteration Detected With NGS in Tumor Tissue and Peripheral Blood in Lung Cancer

Back to course

Pdf Summary

A study conducted at La Paz University Hospital in Madrid sought to evaluate the concordance of gene alterations detected through next-generation sequencing (NGS) in different tissue samples, specifically tumor tissue and peripheral blood, in patients diagnosed with lung cancer. The study included a total of 27 patients, and NGS testing was performed on both tumor tissue and peripheral blood samples. The results showed that in 48.1% of the patients, gene alterations detected in tumor tissue were also found in the circulating tumor DNA (ctDNA) in the blood sample. The most commonly found gene alterations were TP53, MTOR, KRAS, EGFR, and ROS1. Additionally, the study found that NGS results had a clinical impact on one patient's treatment, as a specific mutation detected in both tumor tissue and peripheral blood allowed for the administration of Sotorasib. The study concluded that NGS assays can provide valuable information about the molecular profile of different neoplasms, and liquid biopsy, specifically the analysis of ctDNA in blood samples, can serve as an alternative when tumor tissue is not available for molecular analysis. The high concordance observed between NGS performed on peripheral blood and tumor tissue suggests that this technique may be useful in clinical practice. However, further studies with a larger population are needed to determine the sensitivity of this technique.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

gene alterations

tumor tissue

peripheral blood

lung cancer

NGS testing

ctDNA

molecular profile

liquid biopsy

clinical impact

concordance